equityflowunderstand the flow and follow it

Calluna Pharma

Biotech · Oslo, NO

Antibody therapies for inflammatory and fibrotic diseases

Founders

Jonas Hallen (Norway · ♂) — A physician who met co-founders at Novartis and co-founded Arxx Therapeutics targeting inflammation and fibrosis; when Arxx merged with Oxitope Pharma in 2024 to form Calluna, he continued as co-founder and Chief Medical Officer.
Rizwan Hussain (Norway · ♂) — An entrepreneur and former Novartis colleague who co-founded Arxx Therapeutics in 2019 around DAMP-targeting immunology research, which became Calluna Pharma after the 2024 merger.
Joerg Klingelhoefer (Germany · ♂) — The scientist whose academic research on innate immunity formed the basis of Arxx Therapeutics, the Norwegian company that merged into Calluna Pharma.

Date	Round	Amount
Jan 2024	Series A Norwegian biotech Calluna Pharma, formed by merging Oxitope Pharma and Arxx Therapeutics, raised a EUR 75M Series A led by Forbion.	$81M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.